Home » Vermillion's Aspira Labs Receives New York State Clinical Lab Permit

Vermillion's Aspira Labs Receives New York State Clinical Lab Permit

Jul 13, 2015

NEW YORK (GenomeWeb News) – Vermillion said today that its Aspira Labs subsidiary has received its clinical laboratory permit for the state of New York.

With the New York permit, Aspira is now licensed in all states requiring licensing, allowing the company to process Vermillion's OVA1 ovarian cancer test nationwide.

The permit also marks a milestone in the company's efforts to transition OVA1 testing from Quest Diagnostics to Aspira, which is a key aspect of its new commercial strategy.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Scan

Drive Away the Flies

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

Fewer Transfusions Needed

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

Alteration Here and There to Win

Futurism writes that gene doping could be the next generation of cheating in sports.

This Week in Nature

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.

What's Popular?

In Proteomics & Protein Research

  1. Pan-Cancer Mutation Study Identifies Protein Kinases Key to Tumor Suppression

    Premium

  2. Top Down Proteomics Identifies Protein-Level Effects of KRAS Mutations in Colorectal Cancer

    Premium

  3. Advances in Mass Spec Push Single-Cell Proteomics Toward Feasibility

    Premium

  4. Protagen Shifting to Focus on Cancer Immunotherapy

    Premium

  5. IsoPlexis Uses Single-Cell Platform to Assess T Cell Activity in CAR-T Cancer Therapy

    Premium

Sponsorships

Privacy Policy.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.